Morphosys (MOR) NPV

- Add to watchlist
- This stock can be held in a




Business summary
MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietary Development segment, it develops therapeutic antibodies and peptides in the area of inflammatory disease and oncology. In the Partnered Discovery segment, the Company applies technologies for the research, development and optimization of therapeutic antibodies as drug candidates. The Company develops new treatments for patients suffering from serious diseases. Its technologies include HuCAL, which is a collection fully human antibodies and a system for their optimization; Ylanthia, which is an antibody library in Fab format, and Slonomics, an automated technology for gene synthesis and modification for the generation of gene libraries in a controlled process.
Contact details
Important dates
General stock information
- Short code:
- MOR
- ISIN:
- DE0006632003
- Market cap:
- €789.39 million
- Shares in issue:
- 34.15 million
- Sector:
- Biotechnology
- Exchange:
- Frankfurt Stock Exchange
- Country:
- Germany
- Currency:
- Euro
- Indices:
- n/a
Key personnel

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.